BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that its pivotal Phase 3 study of Natpara® (recombinant human parathyroid hormone (rhPTH[1-84]), known as REPLACE, was published online in The Lancet Diabetes & Endocrinology. Study findings underscore Natpara’s potential as a replacement therapy for endogenous parathyroid hormone (PTH) in hypoparathyroidism, a rare endocrine disorder characterized by insufficient production of PTH, a principal regulator of the body’s mineral homeostasis.
Help employers find you! Check out all the jobs and post your resume.
